Kolleen Stacey Ovarian Cancer Early Detection Program – BioCD Project

KolleenStaceyEarlyDetectionSmall2In recent years, cancer research has benefited from the development of new technologies that enable scientists to perform higher volumes of detailed experiments. That, in turn, has allowed them to cover more ground in their research and make breakthroughs more rapidly than ever before.

One of the biggest beneficiaries of this trend is ovarian cancer research. Because ovarian cancer is characterized by vague early symptoms, it typically goes undiagnosed until it reaches an advanced stage, resulting in a poor prognosis.

Dr. David Nolte disusses his BioCD technology
Dr. David Nolte
(BioCD Technology)
The goal of the Kolleen Stacey Ovarian Cancer Early Detection Program is to leverage recent research advancements to develop a screening test that can detect ovarian cancer at its earliest stage – when it’s most treatable. (The program focuses mainly on epithelial cancers, the most common of the ovarian cancers.)

The most promising breakthrough on this front in some time is the BioCD, developed by Dr. David Nolte, a professor of physics and the director of the adaptive optics and biophotonics group at Purdue University. The BioCD uses a focused laser to rapidly interrogate tens of thousands of antibody spots printed on the surface of a disc.

At WORD, we’re working in partnership with a team of researchers from Purdue University, as well as partners in the private sector, to harness the potential of the BioCD in order to create an early detection test for ovarian cancer a reality.

pdf Kolleen_Stacey_BioCD_Info_Sheet.pdf 235.57 Kb

Last Updated on Monday, 30 August 2010 10:11
©2010 WORDONCANCER.ORG All rights reserved